(Press-News.org) The benefits of hydroxyurea treatment in people with sickle cell disease are well known -- fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center and other institutions reveals that by preventing such complications, the drug can also considerably lower the overall cost of medical care in children with this condition.
The cost-benefit analysis, described online Sept. 2 in the journal Pediatrics and believed to be the first of its kind in pediatric patients, showed that children whose standard care was augmented with daily hydroxyurea incurred, on average, $3,000 less in medical costs per year, compared with children who got standard therapy plus placebo.
"In addition to alleviating the human suffering in sickle cell disease, we found that hydroxyurea had the pleasant 'side effect' of substantially lowering the cost of care among children treated with it," says study investigator James Casella, M.D., director of pediatric hematology at the Johns Hopkins Children's Center. "Our main goal is to find better treatments, but in a time when we are trying to curb health care spending while improving patient outcomes, this is really welcome news."
Although proven valuable in therapy of sickle-cell disease, hydroxyurea remains woefully underused in the treatment of people with this condition, the investigators say. The new findings, the research team says, should encourage more physicians to consider adding hydroxyurea to their patients' therapeutic regimens.
"Our analysis specifically demonstrates an added benefit to the use of hydroxyurea for treatment of sickle cell disease related to the drug's impact on the cost of medical care and should be another factor in support of more widespread use of the drug in both children and adults," says the study's lead investigator Winfred Wang, M.D., of the Hematology Department at St. Jude Children's Research Hospital.
Sickle cell disease, a genetic disorder that affects people of African, Middle Eastern, Mediterranean and Hispanic descent, is marked by abnormally C-shaped or "sickled" red blood cells -- the cells that store and distribute oxygen throughout the body. Because of their abnormal shape, the cells periodically clump inside blood vessels, blocking circulation, which can lead to severe anemia, drive up infection and stroke risk and cause episodes of extreme pain.
Hydroxyurea -- the only FDA-approved drug to treat the excruciating pain crises of sickle cell disease -- works by boosting the levels of a type of hemoglobin that makes red blood cells less likely to bend and clump. Although the drug's beneficial effects on alleviating sickle cell pain were first demonstrated at Johns Hopkins in the mid-1990s, the compound was first synthesized in the late 1800s and has been used mainly in the treatment of certain blood cancers.
In the current study, investigators reviewed the number and cost of hospitalizations among 167 sickle cell patients, ages 1 to 3, treated at three pediatric hospitals between 2003 and 2009. Half of the patients received hydroxyurea in addition to their standard care of pain medication and periodic blood transfusions, while the remainder received standard care plus placebo.
Children treated with hydroxyurea were hospitalized 232 times, compared with 324 hospitalizations among those treated without it. The average cost of hospitalization for children who received hydroxyurea was $9,450 compared with $13,716 among those who received placebo instead. Outpatient treatment was more expensive among children who received hydroxyurea ($1,622 per year), compared with those treated without it ($246), but the higher outpatient cost was offset by fewer hospitalizations and fewer complications. The average cost of all care, including inpatient and outpatient, among children treated with hydroxyurea was $11,072, compared with $13,962 for those treated with placebo.
The lower cost associated with hydroxyurea therapy stems from the compound's ability to prevent or reduce the occurrence of pain crises and serious respiratory complications that require blood transfusions and other treatments, the researchers say. An earlier study by the same group found that children treated with hydroxyurea had fewer such complications than children not receiving the treatment.
About 100,000 people have sickle cell disease in the United States.
###
In addition to Johns Hopkins and St. Jude's, other hospitals participating in the study included Montefiore Medical Center in New York and the State University of New York--Downstate Medical Center/King's County Hospital Center.
The National Heart, Lung and Blood Institute and National Institutes of Health (contracts N01-HB-07150 to N01-HB-07160) funded the study, with partial support from the Best Pharmaceuticals for Children Act and the National Institute of Child Health and Human Development.
Related on the Web:
High Blood Pressure, Anemia Put Children with Sickle Cell Disease at Risk For Silent Strokes http://www.hopkinschildrens.org/High-Blood-Pressure-Anemia-Put-Children-with-Sickle-Cell-Disease-At-Risk-For-Silent-Strokes.aspx
New Sickle Cell Screening Program for
College Athletes Comes with Serious Pitfalls, Experts Say http://www.hopkinschildrens.org/newsDetail.aspx?id=8814&terms=sickle+cell
Flu Shots a Must for Kids with Sickle Cell Disease http://www.hopkinschildrens.org/newsDetail.aspx?id=6488&LangType=1033&terms=sickle+cell
Drug treatment means better, less costly care for children with sickle cell disease
2013-09-11
ELSE PRESS RELEASES FROM THIS DATE:
New system allows cloud customers to detect program-tampering
2013-09-11
CAMBRIDGE, Mass-- For small and midsize organizations, the outsourcing of demanding computational tasks to the cloud — huge banks of computers accessible over the Internet — can be much more cost-effective than buying their own hardware. But it also poses a security risk: A malicious hacker could rent space on a cloud server and use it to launch programs that hijack legitimate applications, interfering with their execution.
In August, at the International Cryptology Conference, researchers from MIT and Israel's Technion and Tel Aviv University presented a new system that ...
Development of a new program that simulates protein movements
2013-09-11
This news release is available in Spanish and Spanish.
Proteins are molecules involved in most of the biological processes that take place in our bodies. They have to move in order to fulfil many of their functions. For example, they open or close to keep and transport the molecules inside them. Until now, costly methods were the only available option for studying these movements: supercomputers were needed and the calculations took many days. The department of mechanics of the Faculty of Engineering in Bilbao has now developed a shorter method. On the basis of ...
'Merlin' is a matchmaker, not a magician
2013-09-11
Johns Hopkins researchers have figured out the specific job of a protein long implicated in tumors of the nervous system. Reporting on a new study described in the Sept. 12 issue of the journal Cell, they detail what they call the "matchmaking" activities of a fruit fly protein called Merlin, whose human counterpart, NF2, is a tumor suppressor protein known to cause neurofibromatosis type II when mutated.
Merlin (which stands for Moesin-Ezrin-Radixin-Like Protein) was already known to influence the function of another protein, dubbed Hippo, but the particulars of that ...
Fires in Argentina Sept. 11, 2013
2013-09-11
Wildfires have broken out in four provinces in Argentina including forest land in Cordoba. The high temperatures and gusty winds have wreaked havoc on the growth of these wildfires and the local meteorologists predict more of the same conditions in the coming days.
According to the Miami Herald: "Cordoba Social Development Minister Daniel Passerini said Tuesday that firefighters are having the toughest time in the central province (near Cordoba) with flames fanned by wind gusts and high temperatures. Passerini says the blaze in Cordoba province has caused the evacuation ...
NASA 3-D image clearly shows wind shear's effect on Tropical Storm Gabrielle
2013-09-11
Data obtained from NASA's TRMM satellite was used to create a 3-D image of Tropical Storm Gabrielle's rainfall that clearly showed wind shear pushed all of the storm's the rainfall east of its center.
NASA's Tropical Rainfall Measuring Mission satellite known as "TRMM" flew directly above tropical Storm Gabrielle on September 10, 2013 at 2124 UTC (5:24 p.m. EDT) as the storm approached Bermuda. TRMM's Precipitation Radar (PR) data found that rain was falling at a rate of over 127mm/~5 inches per hour in a line of intense storms southeast of Bermuda. TRMM PR also found ...
Rim Fire update Sept. 11, 2013
2013-09-11
Firefighters faced extremely hot and dry conditions which contributed to more active fire activity with isolated flare-ups inside current containment lines. The fire is active in the Clavey River Reynolds Creek and Jawbone Creek drainages as well as to the west of Harden Lake, Harden Road and Tioga Road. Moderate fire spread to the northeast into Yosemite Wilderness areas north of Hetch Hetchy reservoir is expected. Unburned tinder within and adjacent to the fire perimeter continue to consume and create spotting near or across planned containment lines. As such the percent ...
International study provides new genetic clue to anorexia
2013-09-11
LA JOLLA, CA—September 11, 2013—The largest DNA-sequencing study of anorexia nervosa has linked the eating disorder to variants in a gene coding for an enzyme that regulates cholesterol metabolism. The finding suggests that anorexia could be caused in part by a disruption in the normal processing of cholesterol, which may disrupt mood and eating behavior.
"These findings point in a direction that probably no one would have considered taking before," said Nicholas J. Schork, a professor at The Scripps Research Institute (TSRI). Schork was the senior investigator for the ...
Trauma centers serving mostly white patients have lower death rates for patients of all races
2013-09-11
Nearly 80 percent of trauma centers in the United States that serve predominantly minority patients have higher-than-expected death rates, according to new Johns Hopkins research. Moreover, the research shows, trauma patients of all races are 40 percent less likely to die — regardless of the severity of their injuries — if they are treated at hospitals with lower-than-expected mortality rates, the vast majority of which serve predominantly white patients.
The findings, described in an article published in the October issue of Annals of Surgery, offer confirmation and ...
Radiotherapy in girls and the risk of breast cancer later in life
2013-09-11
Exposing young women and girls under the age of 20 to ionizing radiation can substantially raise the risk of their developing breast cancer later in life. Scientists may now know why. A collaborative study, in which Berkeley Lab researchers played a pivotal role, points to increased stem cell self-renewal and subsequent mammary stem cell enrichment as the culprits. Breasts enriched with mammary stem cells as a result of ionizing irradiation during puberty show a later-in-life propensity for developing ER negative tumors - cells that do not have the estrogen receptor. Estrogen ...
Low dose antibiotic treatment of C-difficile as effective as high dose in hospital setting
2013-09-11
NEW YORK (September 11, 2013) – Clostridium difficile infection (CDI) treatment in a hospital setting using low dose oral vancomycin showed similar effectiveness compared to high dose, according to a new study by researchers at Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University. These data were presented yesterday at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy meeting in Denver.
Patients with CDI treated with vancomycin at the low dose (LD) (125 mg every 6 hours) and high dose (HD) (greater than ...